Johnson & Johnson reports before the bell today. The stock is popular in part thanks to its 3.3% dividend yield.
Shares of Johnson & Johnson JNJ-1.05% climbed 1.6% in premarket trading Wednesday, after the drugmaker beat second-quarter earnings expectations and raised its full-year outlook, amid strength in sales of cancer treatments and heart health monitoring products.
Johnson & Johnson reported second-quarter profit and raised its full-year sales forecast by around $2 billion on Wednesday as strong demand for its cancer drug, Darzalex, and strength in its medical device business helped it beat Wall Street expectations.
JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.
Johnson & Johnson (NYSE:JNJ) is set to report its earnings on Wednesday, July 16, 2025. For traders focused on events, analyzing historical stock behavior surrounding earnings reports can be an important strategy, possibly improving the odds in your favor.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
These dividend aristocrats haven't disappointed me in 15 years and won't disappoint you either.
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 results due to be announced on the 16th ofJuly. JNJ has a long history of beating consensus EPS estimates by 5.5% on average. The Q2 sales growth could potentially be the weakest of the 4 quarters of the year.
The vast majority of investors don't have hundreds of thousands to bet on each stock.